Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have markedly improved outcomes for patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, acquired resistance remains a critical clinical challenge.Here, we present the case of a 62-year-old male with stage...